TABLE 2.
Multivariate analysis for association of prior treatment with CH-type mutations in glioma patients (N = 135)
| Patient background | Frequency of Potential CH (%) | Multivariate analysis |
|
|---|---|---|---|
| OR (95% CI) | P valuea | ||
| Age b | |||
| ≥56 y (N = 67) vs <56 y (N = 68) | 19% vs 15% | 1.15 (0.44-3.05) | .77 |
|
| |||
| Race/ethnicity | |||
| White (non-Hispanic) (N = 94) vs others (N = 41) | 22% vs 4.9% | 5.94 (1.27-27.71) | .007 |
|
| |||
| WHO grade | |||
| Grade IV/III (N = 118) vs grade II (N = 17) | 19% vs 5.9% | 2.09 (0.23-18.56) | .51 |
|
| |||
| Treatment prior to blood draw | |||
| Temozolomide and radiation (N = 101) vs not (N = 34) | 22% vs 2.9% | 8.98 (1.13-71.46) | .04 |
Abbreviations: cfDNA, cell-free DNA; CH, clonal hematopoiesis; CI, confidence interval; OR, odds ratio; WHO, World Health Organization.
a
The bold values represent the statistically significant P-values (<.05).
b
At the time of blood draw for cfDNA (years), age 56 years is the median and was chosen as the cutoff; other cutoffs, for example, 65 or 70 years, were also not significant (P = .54 and P = .69, respectively).